2003, Number 2
PDF size: 49.26 Kb.
ABSTRACTIntroduction: Use of hormonal replacement therapy is effective to control climacteric symptoms, but there are some risks reported when oral route is used. Therefore, we investigated another via of administration, such as nasal application of estradiol. Nasal via has been studied recently and consists of 17-Β estradiol administration for aspersion in cyclodextrin form to assure immediate activity to the circulation. Method: A group of 20 healthy postmenopausal women aged 51.3 ± 4.7 years of age recruited at the out patient clinic of the Hospital de México in Mexico City. Patients used estradiol administered in each nasal orifice nightly during 3 months, and clinical effect was evaluated by Green scale for climacteric symptoms. Results: All participants reported improvement in symptoms that was statistically significant 21.3 ± 2.3 to 4.5 ± 0.7 (M ± sd p ‹ 0.05). Conclusions: Based on our data, we conclude that nasal administration of estradiol is effective and safe as well as possessing a high degree of acceptance. Hormone replacement must be established individually after evaluating risks and benefits.
Whitcroft SIJ, Stevenson JC. Hormone replacement therapy: risks and benefits. Clin Endocrinol 1992; 36: 15-20.
Zárate A. Algunas recomendaciones terapéuticas en el manejo médico de la menopausia. Rev Fac Med UNAM 1993; 36: 103-106.
Furuhjelm M, Karlgren E, Carlstrôm K. The effect of estrogen therapy on somatic and physical symptoms in postmenopausal women. Acta Obstet Gynecol Scand 1984; 63: 655-661.
Vehkavaara S, Silveira A, Hakala T, VirkamaKi A, Hovatta O, Hamsten A, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoprotein in postmenopausal women. Thromb Haemost 2001; 85: 619-622.
Basurto L, Saucedo R, Ochoa A, Hernández-Valencia M, Zárate A. Terapia de reemplazo hormonal con estradiol transdérmico disminuye los niveles de insulina-cortisol y lipoproteínas en mujeres posmenopáusicas. Ginecol Obst Mex 2002; 70: 491-495.
Jick H, Derby JH, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996; 348: 981-985.
Wattanakumtornkul S, Pinto AB, Williams DB. Intranasal hormone replacement therapy. Menopause 2003; 10: 88-96.
Gottsater M, Rendell UL, Hulthén UL, Berntorp E, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women: a randomized placebo-controlled study of effects on coagulation and fibrinolytic factors. J Int Med 2001; 249: 237-239.
Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on homeostasis variables. Thromb Haemost 1999; 71: 420-424.
Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Brand B, Mauvais-Jarvis P, Sitruk-Ware R. Biological effects of estradiol-17b in postmenopausal women: Oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-541.
Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas PD. Effects of intranasal 17b-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 1999; 84: 2390-2397.
Genazzani AR, Gambacciani M. HRT in the third millennium. Maturitas 2001; 38: S49-S55.